

Progress in fighting antibiotic resistance shown in CDC map

January 12 2018



(HealthDay)—The U.S. Centers for Disease Control and Prevention has



released new data in its Antibiotic Resistance Investment Map, which shows states' progress in combating antibiotic resistance.

This year's map features more than 170 state-reported successes, which include rapidly identifying and containing rare and concerning cases of <u>antibiotic resistance</u>. Multiple successes were reported by each state following the first year of Congress's investment in the CDC's Antibiotic Resistance Solutions Initiative.

The map provides a comprehensive view of resources available for protection from antibiotic resistance. In fiscal year 2016, the CDC made investments in all 50 states, six large cities, and Puerto Rico to improve laboratory and epidemiology expertise, as well as increase public health innovations to address antibiotic resistance. For fiscal year 2017, successes displayed in the map include rapid isolation of a patient with a rare infection, with the containment protocol executed within 48 hours in Tennessee, and reduction of carbapenem-resistant Enterobacteriaceae by 30 percent in 40 facilities in Michigan, preventing more than 300 infections. In addition, whole genome sequencing was used in 38 states and two cities to monitor for outbreaks and identify antibiotic resistance for *Listeria*, *Salmonella*, *Campylobacter*, and *Escherichia coli*.

"This interactive map showcases the work happening on the frontlines of every state and CDC's commitment to keep people safe from drug-resistant infections," CDC Director Brenda Fitzgerald, M.D., said in a statement.

More information: Press Release

Copyright © 2018 HealthDay. All rights reserved.

Citation: Progress in fighting antibiotic resistance shown in CDC map (2018, January 12)



retrieved 26 April 2024 from https://medicalxpress.com/news/2018-01-antibiotic-resistance-shown-cdc.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.